Sharma indicated the company expects to "complete enrollment with 62 to 65 patients across a wide range of solid tumors by the June 2025" for the LP-184 Phase 1a trial, with comprehensive data ...
CEO Panna Sharma stated that "the first quarter of 2025 represents a pivotal inflection point for Lantern Pharma." He highlighted significant progress in the clinical portfolio and the expansion of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback